BML-210
BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].
Product Specifications
CAS Number
537034-17-6
UNSPSC
12352005
Hazard Statement
H302, H361, H372, H410
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BML-210.html
Concentration
10mM
Purity
98.04
Solubility
DMSO : ≥ 30 mg/mL
Smiles
O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
Molecular Formula
C20H25N3O2
Molecular Weight
339.43
Precautions
H302, H361, H372, H410
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Bacillus subtilis Plipastatin synthase subunit B (ppsB), partial
Goose Fibroblast Growth Factor 2 (FGF-2) ELISA Kit
